Olema Pharmaceuticals develops experimental oral drugs for breast cancer, based in San Francisco. It last closed at $7.02 on Nov 20, down 1.82% on the day. The next earnings report for OLMA is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, OLMA reported EPS of -$0.73. Over its last 8 reports the stock moved an average of 7.5% the session after earnings. Over the last 12 months OLMA insiders bought $0 of stock on the open market and sold $24.7M, according to SEC Form 4 filings.
AI Auto Pilots
Is OLMA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OLMA.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on OLMAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
OLMA · as of the Nov 20 close · updated each morning
Downtrend
The stock is 3% below its 20 day and 12% below its 50 day average. It is 80% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the Pivot S1 at $6.81, and the nearest resistance the Pivot at $7.08.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 8.0%/day
Key levels
$36.2652 week high+416.5%
$12.62200 day average+79.8%
$9.56100 day average+36.2%
$7.8450 day average+11.7%
$7.60Swing high (Oct 29)+8.3%
$7.29Pivot R1+3.8%
$7.2520 day average+3.3%
$7.08Pivot+0.9%
$7.02Last close
$6.81Pivot S1−3.0%
$6.71Swing low (Nov 5)−4.4%
$6.2452 week low−11.1%
Indicators
RSI (14)
43.84
Middle of its range
Neutral
MACD
-0.15
Above its signal line
Bullish
Stochastic
23.7
Middle of its range
Neutral
ADX (14)
19.6
No clear trend
Williams %R
-79.9
Oversold below −80, overbought above −20
Neutral
CCI (20)
-49.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−4.2%
Change over 10 sessions
Bearish
ATR (14)
$0.56
Typical daily range, 8.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityLow, 20.8%/day
Key levels
$36.2652 week high+416.5%
$12.62200 day average+79.8%
$9.56100 day average+36.2%
$7.8450 day average+11.7%
$7.60Swing high (Oct 29)+8.3%
$7.29Pivot R1+3.8%
$7.2520 day average+3.3%
$7.08Pivot+0.9%
$7.02Last close
$6.81Pivot S1−3.0%
$6.71Swing low (Nov 5)−4.4%
$6.2452 week low−11.1%
Indicators
RSI (14)
33.86
Weak, oversold below 30
Neutral
MACD
-1.84
Below its signal line
Bearish
Stochastic
18.6
Near the bottom of its range
Oversold
ADX (14)
29.9
Trending down
Williams %R
-84.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-89.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−31.3%
Change over 10 sessions
Bearish
ATR (14)
$1.46
Typical daily range, 20.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OLMA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OLMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow OLMA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for OLMAHow many large options trades hit OLMA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in OLMA in the last 90 days.
From SEC Form 4 filings by OLMA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OLMA is in one of them and how their past OLMA trades turned out.
Olema Pharmaceuticals is a drug developer based in San Francisco, California. It is developing oral medicines for breast cancer, led by palazestrant, an experimental drug that blocks the estrogen receptor and breaks it down. The company is also developing OP3136, a treatment that targets the KAT6 protein. If approved, these drugs would be prescribed to women with breast cancer. None of its products are approved for sale yet, so it has no product sales.